Hiramatsu Hiroyuki, Suzuki Ryota, Yamada Shigeki, Ihira Masaru, Isegawa Yuji, Kawamura Yoshiki, Matsuoka Erina, Miura Hiroki, Yoshikawa Tetsushi
Department of Clinical Pharmacy, Fujita Health University Hospital, Aichi, Japan.
Faculty of Clinical Engineering, Fujita Health University School of Health Sciences, Aichi, Japan.
Antimicrob Agents Chemother. 2015 May;59(5):2618-24. doi: 10.1128/AAC.04692-14. Epub 2015 Feb 17.
Quenching probe PCR (QP-PCR) analysis was used to determine the frequency of ganciclovir (GCV) resistance among clinical isolates of human herpesvirus 6B (HHV-6B) obtained from patients with primary viral infection and viral reactivation. Forty-two HHV-6B clinical isolates were repeatedly recovered from 15 hematopoietic stem cell transplant (HSCT) recipients, and 20 isolates were recovered from 20 exanthem subitum (ES) patients. Of the 15 HSCT recipients, 9 received GCV during the observation period; however, none of the ES patients were treated with GCV. Two established laboratory strains, Z29 and HST, were used as standards in this study. Regions 1 and 2 of the U69 gene of all of the clinical isolates demonstrated the same melting temperature as regions 1 and 2 of the Z29 strain. For region 3, the melting temperatures of all clinical isolates fell between the melting temperature of the plasmid containing the A462D single nucleotide polymorphism (SNP) and the melting temperature of the Z29 strain, and the melting temperatures profiles of all clinical isolates were similar to the melting temperature profile of the Japanese HST strain. As expected, none of the 20 clinical isolates recovered from the ES patients and the 14 isolates recovered from the HSCT recipients who did not receive GCV treatment carried the six known SNPs associated with GCV resistance. Interestingly, these six SNPs were not detected in the 28 clinical isolates recovered from the 9 HSCT recipients who received GCV. Additional sequence analysis of the U69 gene from the 15 representative isolates from the 15 HSCT recipients identified other SNPs. These SNPs were identical to those identified in the HST strain. Therefore, the rate of emergence of GCV-resistant HHV-6B strains appears to be relatively low, even in HSCT recipients treated with GCV.
采用淬灭探针聚合酶链反应(QP-PCR)分析法,以确定从原发性病毒感染和病毒再激活患者中获得的人疱疹病毒6B(HHV-6B)临床分离株中更昔洛韦(GCV)耐药的频率。从15例造血干细胞移植(HSCT)受者中反复分离出42株HHV-6B临床分离株,从20例幼儿急疹(ES)患者中分离出20株。在15例HSCT受者中,9例在观察期内接受了GCV治疗;然而,ES患者均未接受GCV治疗。本研究采用两种已建立的实验室菌株Z29和HST作为标准。所有临床分离株U69基因的区域1和区域2显示出与Z29菌株的区域1和区域2相同的解链温度。对于区域3,所有临床分离株的解链温度介于含有A462D单核苷酸多态性(SNP)的质粒的解链温度和Z29菌株的解链温度之间,并且所有临床分离株的解链温度曲线与日本HST菌株的解链温度曲线相似。正如预期的那样,从ES患者中分离出的20株临床分离株以及从未接受GCV治疗的HSCT受者中分离出的14株分离株均未携带与GCV耐药相关的6个已知SNP。有趣的是,在从接受GCV治疗的9例HSCT受者中分离出的28株临床分离株中未检测到这6个SNP。对来自15例HSCT受者的15株代表性分离株的U69基因进行的额外序列分析鉴定出了其他SNP。这些SNP与在HST菌株中鉴定出的SNP相同。因此,即使在接受GCV治疗的HSCT受者中,GCV耐药的HHV-6B菌株的出现率似乎也相对较低。